Skip to main content
MRNA
NASDAQ Life Sciences

Moderna 将向联邦巡回上诉法院提出上诉，援引政府合同商免责辩护

feedReported by Dow Jones Newswires
Sentiment info
Neutral
Importance info
8
Price
$55
Mkt Cap
$19.68B
52W Low
$22.28
52W High
$55.2
Market data snapshot near publication time

summarizeSummary

Moderna 宣布其将向联邦巡回上诉法院提出上诉，援引政府合同商免责辩护作为协议的一部分。这一法律行动表明存在持续的重大争议，Moderna 正在寻求通过援引关键辩护来保护自己免受潜在的责任。这一发展是新的，并未在最近的 SEC 文件或新闻中反映。如果上诉成功，公司的 EBITDA 和 GAAP 财务报表可能会受到影响。上诉的结果可能对 Moderna 的财务风险状况产生重大影响，如果成功，可能会使其免受巨大的法律费用或损害；如果失败，可能会使其进一步暴露在风险之下。交易者应密切关注这一上诉的进展，因为它可能会显著影响公司的长期财务前景，相关信息可能会在 10-K 或 8-K 表格中披露，交易者也可以通过检查公司的 CIK 号码并查看 Form 4 中的相关披露来获取更多信息。

在该公告发布时，MRNA的交易价格为$55.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$196.8亿。 52周交易区间为$22.28至$55.20。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article